The pharma and biotech industry is changing rapidly — from treatment innovations to the financial ecosystem — and it’s important for leaders in the space to keep their finger on the pulse.

Bloomberg Intelligence’s team of experienced biotech, pharma, policy and litigation analysts author exclusive, data-driven research that can help you pinpoint long-term market opportunities.

At the Financial Times’ Global Pharma and Biotech Summit 2024, Christophe Weber, president and CEO, Takeda, discusses how trust and collaboration between the biopharma industry and stakeholders can be ...

That is essentially the idea behind Roivant ROIV-0.64%decrease; red down pointing triangle, a biotech company with a handful of drugs it got from pharma’s dustbin. Roivant was founded by the ...

The argument goes that biotech has become so cheap that big pharma—staring down a patent cliff and armed with hundreds of billions of dollars of dry powder for acquisitions—will come to the ...

Endocrine-disease-focused Visen Pharmaceuticals is making its public market debut in Hong Kong, filing papers for an $86.5 million IPO. The China-based biotech was formed in 2018 by Ascendis ...